Hamilton Health Sciences Corporation

🇨🇦Canada

Country: 🇨🇦Canada

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

Radiation Therapy Followed by Durvalumab (MEDI4736) and Tremelimumab And Surgery Versus Radiation Therapy Followed by Surgery for Resectable Hepatocellular Carcinoma.

Phase 3

Not yet recruiting

Conditions: Hepatocellular Carcinoma (HCC)

Interventions: Drug: Chemotherapy/Radiation

First Posted Date: 2025-06-18

Last Posted Date: 2025-06-18

Lead Sponsor: Hamilton Health Sciences Corporation

Target Recruit Count: 30

Registration Number: NCT07027436

Locations: 🇨🇦
Juravinski Hospital, Hamilton, Ontario, Canada

Intravascular Ultrasound for Peripheral Artery Disease Revascularization

Not Applicable

Not yet recruiting

Conditions: Peripheral Arterial Disease(PAD)
Chronic Limb Threatening Ischemia
Intravascular Ultrasound
Major Adverse Limb Events
Restenosis

First Posted Date: 2025-05-18

Last Posted Date: 2025-05-18

Lead Sponsor: Hamilton Health Sciences Corporation

Target Recruit Count: 772

Registration Number: NCT06979284

Health Literacy in Geriatric Patients

Recruiting

Conditions: Health Literacy

First Posted Date: 2025-05-14

Last Posted Date: 2025-05-18

Lead Sponsor: Hamilton Health Sciences Corporation

Target Recruit Count: 100

Registration Number: NCT06971393

Locations: 🇨🇦
St. Peter's Geriatric Clinic, Hamilton, Ontario, Canada

Investigation of GLP1-Receptor Agonists in Men With Prostate Cancer Taking Androgen Deprivation Therapy

Phase 4

Not yet recruiting

Conditions: Prostate Cancer

Interventions: Drug: Semaglutide Pen Injector

First Posted Date: 2025-04-03

Last Posted Date: 2025-04-03

Lead Sponsor: Hamilton Health Sciences Corporation

Target Recruit Count: 20

Registration Number: NCT06908694

Locations: 🇨🇦
Juravinski Cancer Centre, Hamilton, Ontario, Canada

SCORE! ACTIVE Trial

Not Applicable

Recruiting

Conditions: Chronic Disease
Childhood Obesity

First Posted Date: 2025-02-25

Last Posted Date: 2025-02-25

Lead Sponsor: Hamilton Health Sciences Corporation

Target Recruit Count: 1400

Registration Number: NCT06844786

Locations: 🇨🇦
McMaster University, Hamilton, Ontario, Canada

A Trial of Actazin Versus PEG 3350 for Maintenance Therapy in Children With Constipation

Phase 2

Not yet recruiting

Conditions: Constipation - Functional
Constipation
Constipation Aggravated

Interventions: Dietary Supplement: Actazin chewable tablet
Drug: PEG 3350
Other: Chewable Tablet
Other: Maltodextrin (Placebo)

First Posted Date: 2025-02-20

Last Posted Date: 2025-03-19

Lead Sponsor: Hamilton Health Sciences Corporation

Target Recruit Count: 60

Registration Number: NCT06836024

Locations: 🇨🇦
Hamilton Health Sciences, Hamilton, Ontario, Canada

CCTA to Optimize Diagnostic Yield of Invasive Angiography With AI

Not Applicable

Recruiting

Conditions: Coronary Artery Disease

First Posted Date: 2024-10-18

Last Posted Date: 2025-01-30

Lead Sponsor: Hamilton Health Sciences Corporation

Target Recruit Count: 252

Registration Number: NCT06648239

Locations: 🇨🇦
Hamilton General Hospital, Hamilton, Ontario, Canada
🇨🇦
McMaster University Medical Centre, Hamilton, Ontario, Canada
🇨🇦
St. Catharines Hospital, St. Catharines, Ontario, Canada

Decreasing Postoperative Blood Loss and Seizures by Timing of Intravenous Tranexamic Acid 2 Pilot Trial

Phase 3

Not yet recruiting

Conditions: Bleeding
Surgical Blood Loss
Seizures

Interventions: Drug: After CPB Tranexamic Acid
Drug: Before CPB Tranexamic Acid
Drug: Before CPB Placebo
Drug: After CPB Placebo

First Posted Date: 2024-10-02

Last Posted Date: 2024-10-02

Lead Sponsor: Hamilton Health Sciences Corporation

Target Recruit Count: 40

Registration Number: NCT06622564

Locations: 🇨🇦
Hamilton Health Sciences - General Hospital, Hamilton, Ontario, Canada

Prevention of Infections in Cardiac Surgery (PICS): a Cluster-randomized Factorial Cross-over Trial

Phase 4

Not yet recruiting

Conditions: Infection, Surgical Site

Interventions: Drug: Cefazolin
Drug: Vancomycin

First Posted Date: 2024-08-23

Last Posted Date: 2025-06-13

Lead Sponsor: Hamilton Health Sciences Corporation

Target Recruit Count: 38000

Registration Number: NCT06567808

Vitaliti Continuous Vital Signs Monitor User-Testing Protocol: VERDICT-2

Not Applicable

Not yet recruiting

Conditions: Surgery

Interventions: Other: User-testing of Vitaliti Continuous Vital Sign Monitor Model CVSM-1A

First Posted Date: 2024-06-18

Last Posted Date: 2024-06-18

Lead Sponsor: Hamilton Health Sciences Corporation

Target Recruit Count: 45

Registration Number: NCT06464094

Locations: 🇨🇦
McMaster University, Hamilton, Ontario, Canada

AI-Powered Research

Premium Access

Hamilton Health Sciences Corporation

Radiation Therapy Followed by Durvalumab (MEDI4736) and Tremelimumab And Surgery Versus Radiation Therapy Followed by Surgery for Resectable Hepatocellular Carcinoma.

Intravascular Ultrasound for Peripheral Artery Disease Revascularization

Health Literacy in Geriatric Patients

Investigation of GLP1-Receptor Agonists in Men With Prostate Cancer Taking Androgen Deprivation Therapy

SCORE! ACTIVE Trial

A Trial of Actazin Versus PEG 3350 for Maintenance Therapy in Children With Constipation

CCTA to Optimize Diagnostic Yield of Invasive Angiography With AI

Decreasing Postoperative Blood Loss and Seizures by Timing of Intravenous Tranexamic Acid 2 Pilot Trial

Prevention of Infections in Cardiac Surgery (PICS): a Cluster-randomized Factorial Cross-over Trial

Vitaliti Continuous Vital Signs Monitor User-Testing Protocol: VERDICT-2